MorphoSys Expands Antibody Development Deal with Pfizer Three Years

Dec 20, 2006

NEW YORK (GenomeWeb News) — MorphoSys today said it has expanded by three years its collaboration with drug giant Pfizer for the development of antibody therapeutics.

The agreement builds upon a deal struck in 2003 scheduled to end in 2008. The new deal extends the collaboration to 2011 and includes a one-off payment from Pfizer, MorphoSys said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Helix Launches 'App Store'

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

More CAR-T Therapies Sought

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Telomeres of Spawning Salmon

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

This Week in PLOS

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.

Main menu